menu toggle
As we continue to evolve our brand to Cencora, you will continue to see visual changes. We will be sunsetting amerisourcebergen.com over time and are actively moving content and information over to cencora.com. Please visit cencora.com if you can't find what you are looking for here.

Report: Building successful cell and gene therapy supply chains

By AmerisourceBergen

This report from Scrip Pharma Intelligence summarizes the takeaways from a recent roundtable with a panel of experts representing early stage biotech, pharmaceutical, supply chain management and logistics companies:

  • Orchestrating cell and gene therapies requires bespoke solutions in terms of storage, transportation, timelines, temperature control, and servicer flexibility
  • In these incredibly complex supply chains, forming and orchestrating partnerships is a necessity
  • In order for logistics vendors to form partnerships with cell and gene therapy manufacturers it is important to understand each company's unique requirements
  • Scalability of logistics solutions is also an important consideration